Intensity Therapeutics Secures $2M to Propel INT230-6 After 75% Disease Control

Introduction to the Company

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical-stage biotechnology firm headquartered in Shelton, Connecticut. The company utilizes its proprietary DfuseRx™ discovery platform to develop intratumoral cancer therapies. Its lead candidate, INT230-6, combines the cytotoxic agents cisplatin and vinblastine with an amphiphilic molecule intended for direct injection into solid tumors, aiming to target cancer cells locally while also stimulating systemic immune activation.

Corporate Structure and Experience

Intensity employs between 2 and 10 staff members, consisting of professionals specializing in oncology research, clinical trial operations, and regulatory affairs. The leadership team includes individuals with experience in immuno-oncology development and pharmaceutical management. The company collaborates with academic institutions, including the University of Southern California’s Norris Comprehensive Cancer Center, for its clinical programs.

Cancer therapy by National Cancer Institute

Recent Developments and News

• Public Offering (June 11–13, 2025): Intensity completed an underwritten offering of 6,675,000 common shares at $0.30 each, raising approximately $2.0 million before expenses. The proceeds are allocated for patient enrollment and data readouts in the INVINCIBLE-3 Phase 3 sarcoma trial, as well as supporting the INVINCIBLE-4 Phase 2/3 study for triple-negative breast cancer.
• eBioMedicine Publication (October 30, 2025): The Lancet Discovery Science journal published data from the Phase 1/2 IT-01 study, which indicated a 75% disease control rate and a median overall survival of 11.9 months in 64 heavily pretreated patients. In a sarcoma subset, a median survival of 21.3 months was observed. Abscopal effects were noted in 20% of patients receiving doses that covered more than 40% of tumor burden. A webinar featuring investigators from USC was held on October 31, 2025.
• SEC Filings: An 8-K was filed on October 23, 2025 (Item 5.07), and another on September 10, 2025 (Item 8.01), with no material restatements reported. A DEFA14A proxy statement was submitted on September 9, 2025, prior to a shareholder meeting.

Financial and Strategic Aspects

As of October 30, 2025, Intensity’s stock closed at $0.8057, a decline of 38.96% year-to-date, with a trading volume of approximately 65.3 million shares. The 52-week trading range is between $0.1850 and $3.4000. The market capitalization is near $56 million, with an enterprise value of $11.15 million. The balance sheet reflects $2.22 million in cash, a debt-to-equity ratio of 5.7%, and negative free cash flow of $6.34 million over the trailing twelve months. The net loss for that period was approximately $12.6 million, resulting in a diluted EPS of -$0.82.

Strategically, the company is advancing INT230-6 through late-stage trials in metastatic sarcoma and triple-negative breast cancer. A shelf registration statement (S-3) was filed on July 3, 2024, to support potential future equity financings as development milestones are achieved.

Market Position and Industry Context

Intensity operates in the immuno-oncology sector, focusing on intratumoral therapeutic approaches that may complement systemic immunotherapies. Its direct injection method is designed to address the challenges presented by the dense microenvironment of solid tumors, which is a specific area within a broader market dominated by checkpoint inhibitors, targeted small molecules, and cell therapies. The company has a beta of 3.67, indicative of the volatility typical of small-cap, clinical-stage biotechnology stocks.

tl;dr

Intensity Therapeutics concluded a $2.0 million public offering on June 13, 2025, to finance its INVINCIBLE-3 and INVINCIBLE-4 trials. On October 30, 2025, eBioMedicine published the Phase 1/2 results for INT230-6, reporting a 75% disease control rate and 11.9-month median survival, with abscopal effects observed in 20% of high-dose patients. A follow-up webinar took place on October 31, 2025. With $2.22 million in cash and a shelf registration in place, the company aims to advance its late-stage clinical programs through upcoming data readouts.